Do Epilepsy Patients with Cognitive Impairment Have Alzheimer's Disease-like Brain Metabolism?
Michael HeTiffany A KolesarAndrew L GoertzenMarcus C NgJi Hyun KoPublished in: Biomedicines (2023)
Although not classically considered together, there is emerging evidence that Alzheimer's disease (AD) and epilepsy share a number of features and that each disease predisposes patients to developing the other. Using machine learning, we have previously developed an automated fluorodeoxyglucose positron emission tomography (FDG-PET) reading program (i.e., MAD), and demonstrated good sensitivity (84%) and specificity (95%) for differentiating AD patients versus healthy controls. In this retrospective chart review study, we investigated if epilepsy patients with/without mild cognitive symptoms also show AD-like metabolic patterns determined by the MAD algorithm. Scans from a total of 20 patients with epilepsy were included in this study. Because AD diagnoses are made late in life, only patients aged ≥40 years were considered. For the cognitively impaired patients, four of six were identified as MAD+ (i.e., the FDG-PET image is classified as AD-like by the MAD algorithm), while none of the five cognitively normal patients was identified as MAD+ (χ 2 = 8.148, p = 0.017). These results potentially suggest the usability of FDG-PET in prognosticating later dementia development in non-demented epilepsy patients, especially when combined with machine learning algorithms. A longitudinal follow-up study is warranted to assess the effectiveness of this approach.
Keyphrases
- positron emission tomography
- end stage renal disease
- machine learning
- ejection fraction
- newly diagnosed
- computed tomography
- chronic kidney disease
- peritoneal dialysis
- depressive symptoms
- cognitive impairment
- pet ct
- magnetic resonance imaging
- healthcare
- working memory
- blood brain barrier
- pet imaging
- artificial intelligence
- randomized controlled trial
- subarachnoid hemorrhage
- white matter